IBM doesn’t refer to its newest life science initiative as “information-based medicine” for nothing. Speaking at a biotech investors’ conference in New York earlier this month, IBM’s worldwide operations manager for life sciences, Joe Jasinski, quipped that it would be just fine with Big Blue if the term’s acronym —which is (ahem) IBM — happens to find its way into common parlance. After all, his company is planning to provide the IT infrastructure that would make such a vision possible.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.